Brokerages expect Omeros Co. (NASDAQ:OMER) to report earnings per share of ($0.63) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings. The highest EPS estimate is ($0.57) and the lowest is ($0.69). Omeros reported earnings of ($0.25) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 152%. The business is expected to report its next quarterly earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Omeros will report full-year earnings of ($2.67) per share for the current year, with EPS estimates ranging from ($2.71) to ($2.62). For the next fiscal year, analysts expect that the firm will report earnings of ($1.13) per share, with EPS estimates ranging from ($2.04) to ($0.22). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Omeros.
Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The company had revenue of $4.61 million during the quarter, compared to analyst estimates of $3.07 million. During the same quarter in the previous year, the business posted ($0.16) EPS.
OMER traded down $0.52 during trading hours on Friday, reaching $13.96. The company’s stock had a trading volume of 631,419 shares, compared to its average volume of 1,005,956. Omeros has a 52 week low of $8.36 and a 52 week high of $27.00. The stock has a market cap of $673.88 million, a PE ratio of -17.67 and a beta of 3.79.
In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of the company’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $25.75, for a total value of $193,871.75. Following the transaction, the vice president now directly owns 227,645 shares of the company’s stock, valued at approximately $5,861,858.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 12.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ingalls & Snyder LLC grew its holdings in Omeros by 1.3% in the 2nd quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock valued at $101,829,000 after buying an additional 70,625 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Omeros by 1.0% during the 3rd quarter. BlackRock Inc. now owns 3,957,936 shares of the biopharmaceutical company’s stock worth $96,614,000 after purchasing an additional 38,349 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Omeros by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,427 shares of the biopharmaceutical company’s stock worth $53,810,000 after purchasing an additional 34,043 shares in the last quarter. Cpwm LLC grew its holdings in shares of Omeros by 5.0% during the 2nd quarter. Cpwm LLC now owns 1,074,543 shares of the biopharmaceutical company’s stock worth $19,492,000 after purchasing an additional 51,015 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Omeros by 2.1% during the 2nd quarter. Northern Trust Corp now owns 615,377 shares of the biopharmaceutical company’s stock worth $11,162,000 after purchasing an additional 12,827 shares in the last quarter. 48.48% of the stock is currently owned by hedge funds and other institutional investors.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: The benefits and drawbacks of dollar cost averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.